Vale Professor Ronald Jones

NZX/ASX Announcement
23 April 2025
Vale Professor Ronald Jones
• Professor Ronald William Jones CNZM?.MB.ChB?.MD.(Otago)?.FRCS.(Ed¡)?.FRCOG¡?
FRANZCOG? passed away peacefully on 31 March 2025.
• Prof. Ron Jones was a key developer of the TruScreen cervical cancer screening
technology and was a member of the TruScreen medical advisory committee from
2015, and latterly, a Non-Executive Director 2017-2021.

Professor Ronald William Jones CNZM, MB ChB, MD (Otago), FRCS (Ed.), FRCOG., FRANZCOG, passed
away peacefully on 31 March 2025.
TruScreen is privileged to have worked in close collaboration with Professor Jones in the development of
the TruScreen technology, especially on its AI-enabled algorithm in 2012. Prof. Jones was involved with
the TruScreen technology since inception and was the Principal Investigator for a 1,998-patient study at
National Women’s Hospital in Auckland, one of the key clinics used to gather early data for what was
then the Cervical PolarProbe (the predecessor prototype of TruScreen).
He was a member of the TruScreen medical advisory committee from 2015, and a Non-Executive
Director 2017-2021.
Professor Jones was a prominent globally renowned New Zealand gynaecologist, and a former clinical
professor at the University of Auckland. He wa s a widely published international authority on lower
genital tract pre-cancer and cancer, and past President of the International Society for the Study of
Vulvovaginal Disease and chair of the Scientific Committee of the International Federation of Cervical
Pathology and Colposcopy.
In 2017 he published a NZ bestselling book Doctors in Denial: The Forgotten Women in the ‘Unfortunate
Experiment’ exposing a dark history in cervical cancer study during the 1960s-1970s in Auckland, New
Zealand.
Prof. Jones led the technical presentation to the All India Institute of Medical Science (AIIMS) in Delhi,
India. Resulting from his efforts in November 2017, a pilot study of 1,000 patients was successfully
completed. The COVID 19 pandemic interrupted further development of TruScreen into the Indian sub-
continent. TruScreen will continue with the pioneering work of Prof. Jones in India and will shortly appoint
a distributor in India.
Prof. Jones was a champion of women's health. His dedication and contributions to the understanding of
cervical cancer and gynaecological pathology will continue to impact countless lives for years to come
and we will remain indebted to his service.
Chairman Tony Ho and CEO, Martin Dillon met with Prof. Jones in Auckland in August 2024 to brief him of
the commercial acceptance of the TruScreen AI enabled technology in a number of key markets.
We will miss Prof. Jones’ counsel.

On behalf of the board and staff of TruScreen, our thoughts are with his family for the loss of a great
New Zealander.
This announcement has been approved by the Board.

Ends


For more information, visit www.truscreen.com or contact:
Tony Ho
Chairman
t
onyho@truscreen.com

Martin Dillon
Chief Executive Officer
m
artindillon@truscreen.com